Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors DOI Creative Commons
Antongiulio Faggiano, Flaminia Russo, Virginia Zamponi

и другие.

Journal of Neuroendocrinology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 26, 2024

Abstract Dyslipidemia is a potential unfavorable prognostic factor in neuroendocrine tumors (NETs); conversely, statins proved to have antiproliferative effects NET cell lines and could be helpful therapeutic strategy for these patients. The main objective of this observational cohort retrospective study explore the associations between dyslipidemia progression evaluate influence context. 393 patients with histologically confirmed gastroenteropancreatic or bronchopulmonary NETs from six Italian centres didicated diagnosis therapy were included. included 123 dyslipidemia, 81 which taking statins. Clinicopathological data, including patient demographics, tumor characteristics, treatment details as well prevalence, timing hypolipemic collected. outcome measure used progression‐free survival (PFS). Among patients, (31.3%) had dyslipidemia. Statins by (65.8%) dyslipidemic mostly atorvastatin. Median PFS was 87 months overall, 124 non‐dyslipidemic 72 ( p = .268). Dyslipidemic on significantly better median (108 months) than those not (26 months; .024). Recurrence‐free (RFS) also evaluated, but no significant differences found. In conclusion, while lower compared difference statistically significant. Statin associated improved among suggesting effect NETs. These findings warrant further investigation substantiate role management

Язык: Английский

Development of a Nomogram‐Based Online Calculator for Predicting Cancer‐Specific Survival in Patients With Digestive Tract Mixed Neuroendocrine‐Non‐Neuroendocrine Neoplasms (MiNENs): An Analysis of the SEER Database DOI Creative Commons
Jing Tang, Siqi Wei,

Guobin Tang

и другие.

Cancer Reports, Год журнала: 2025, Номер 8(2)

Опубликована: Фев. 1, 2025

ABSTRACT Aims Mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs) represent a rare and heterogeneous subgroup of that typically consist neuroendocrine (NE) component, most commonly carcinoma (NEC), alongside non‐neuroendocrine (non‐NE) component. They occur in the digestive tract, their prognosis is influenced by multiple factors. This article aimed to identify factors affect cancer‐specific survival (CSS) MiNENs develop an effective nomogram‐based online calculator validate its effectiveness. Methods The clinical, pathological, epidemiological, data patients with tract were collected from Surveillance, Epidemiology, End Results (SEER) database spanning 2000 2020. Then, dataset was divided into training cohort validation cohort. χ 2 test or Fisher's exact utilized assess differences demographic clinicopathological characteristics between two groups. Kaplan–Meier curves log‐rank tests employed conduct analysis. Additionally, univariate multivariate Cox regression analyses performed potential prognostic nomograms for predicting CSS at 1, 3, 5 years. Lastly, predictive ability subsequently compared sixth edition American Joint Committee on Cancer (AJCC) TNM staging system using Harrell concordance index (C‐index), area under receiver operating characteristic curve (AUC), calibration curve, decision analysis (DCA). A total 330 randomly assigned groups, namely, ( n = 231) 99). revealed significant association lower cumulative age ≥ 65 years, poor tumor grade, lack surgical treatment, stages III IV, distant metastasis. In cohort, nomogram incorporating surgery, stage, metastasis developed, which demonstrated favorable discriminatory capabilities. Compared staging, exhibited satisfactory performance 1‐year, 3‐year, 5‐year rates. C‐index value 0.787 0.738 respectively. achieved AUC 85.81%, 85.86%, 87.32% 1‐year CSS, 3‐year contrast, these values 78.46%, 81.50%, 83.88% Conclusions developed offers novel approach MiNENs. Indeed, it can accurately predict over thereby assisting enhancing formulating appropriate treatment strategies.

Язык: Английский

Процитировано

0

Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist DOI
Francesca Spada, Roberto Rossi, Roberta Modica

и другие.

Cancer Treatment Reviews, Год журнала: 2025, Номер 135, С. 102907 - 102907

Опубликована: Фев. 27, 2025

Язык: Английский

Процитировано

0

The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms DOI
Hao Zhou, Yong Zhu, Bin Qin

и другие.

Endocrine, Год журнала: 2024, Номер unknown

Опубликована: Июнь 6, 2024

Язык: Английский

Процитировано

1

Investigating the causal relationship between gut microbiota and gastroenteropancreatic neuroendocrine neoplasms: a bidirectional Mendelian randomization study DOI Creative Commons
Chunyu Zhang,

Shi-jing Jiang,

Jingjing Cao

и другие.

Frontiers in Microbiology, Год журнала: 2024, Номер 15

Опубликована: Авг. 13, 2024

Background The interaction between the intestinal flora and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) remains poorly understood, despite known effect of gut microbiota on gastrointestinal adenocarcinomas. Hence, present research aimed to determine potential causal correlation GEP-NENs by conducting a bidirectional Mendelian randomization (MR) analysis. Methods Two-sample MR analysis was conducted using summary statistics from MiBioGen consortium those FinnGen project. inverse-variance weighted approach utilized as primary analytical method. To enhance robustness our findings, multiple sensitivity tests were performed, including Cochran’s Q test for evaluating heterogeneity, MR-Egger intercept detect horizontal pleiotropy, MR-PRESSO identify outliers assess pleiotropy bias. Additionally, leave-one-out performed validate consistency findings. MR-Steiger also direction in GEP-NENs. Finally, reverse causality Results We identified 42 taxa that potentially causally associated with GEP-NENs; these taxa, 7, 8, 11, 16 pancreatic NENs, colorectal small gastric respectively. After adjusting false discovery rate (FDR) correction, we found significant links Euryarchaeota NENs Family XIII UCG-001 NENs. analyses confirmed stability correlations. In analysis, be variations 8 6 different microbiota, FDR no detected flora. Conclusion study reveals association certain GEP-NENs, thus providing new perspectives regarding role development tumors. These insights could provide innovative approaches screen prevent diseases.

Язык: Английский

Процитировано

1

Neuroendocrine tumors and survival rates in MEN-1 patients: impact of gender difference DOI
Roberta Modica, Alessia Liccardi, Roberto Minotta

и другие.

Neuroendocrinology, Год журнала: 2024, Номер unknown, С. 1 - 7

Опубликована: Окт. 28, 2024

Introduction: Multiple endocrine neoplasia type 1 (MEN-1) is the most common inherited syndrome associated with NET development and gender-specific differences are emerging in neuroendocrine tumors (NETs). This study aimed to analyze gender difference a single cohort of MEN-1 patients focusing on duodeno-pancreatic (DP)-NET survival rates. Methods: referred Endocrinology Unit “Federico II” University Naples, ENETS CoE, were retrospectively evaluated. Results: Among 100 enrolled, 59 (59%) female 41 (41%) male, mean age at diagnosis was 39.4 years (range 5–86). No statistically significant association identified between clinical manifestations (primary hyperparathyroidism [PHPT] p: 1.0, DP-NET 0.83, pituitary adenoma [PA] 0.84, lung 0.64, thymic 0.10), similarly, its individual similar genders. Survival analysis revealed no genders regarding progression disease 1.0 death 1.0. Mean progression-free (PFS) 98.6 months 3–288), overall (OS) 130.1 3–444 months), without (PFS 0.67 OS 0.60). The Kaplan-Meier curves for PFS showed 0.92; 0.87). Conclusion: In this cohort, occurrence PHPT, PA, DP-NET, NET, nor outcomes including within subcohort, emerged. Therefore, supports screening follow-up both male patients.

Язык: Английский

Процитировано

0

Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors DOI Creative Commons
Antongiulio Faggiano, Flaminia Russo, Virginia Zamponi

и другие.

Journal of Neuroendocrinology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 26, 2024

Abstract Dyslipidemia is a potential unfavorable prognostic factor in neuroendocrine tumors (NETs); conversely, statins proved to have antiproliferative effects NET cell lines and could be helpful therapeutic strategy for these patients. The main objective of this observational cohort retrospective study explore the associations between dyslipidemia progression evaluate influence context. 393 patients with histologically confirmed gastroenteropancreatic or bronchopulmonary NETs from six Italian centres didicated diagnosis therapy were included. included 123 dyslipidemia, 81 which taking statins. Clinicopathological data, including patient demographics, tumor characteristics, treatment details as well prevalence, timing hypolipemic collected. outcome measure used progression‐free survival (PFS). Among patients, (31.3%) had dyslipidemia. Statins by (65.8%) dyslipidemic mostly atorvastatin. Median PFS was 87 months overall, 124 non‐dyslipidemic 72 ( p = .268). Dyslipidemic on significantly better median (108 months) than those not (26 months; .024). Recurrence‐free (RFS) also evaluated, but no significant differences found. In conclusion, while lower compared difference statistically significant. Statin associated improved among suggesting effect NETs. These findings warrant further investigation substantiate role management

Язык: Английский

Процитировано

0